Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
This analysis evaluates Biogen Inc.’s (NASDAQ: BIIB) recently announced definitive licensing agreement with TJ Biopharma for Greater China rights to experimental antibody felzartamab, a key late-stage asset in the firm’s immunology pipeline. The $850 million total potential deal unlocks full global
Biogen Inc. (BIIB) - Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares Rally - Beat Estimates
BIIB - Stock Analysis
3404 Comments
1348 Likes
1
Herve
Senior Contributor
2 hours ago
Wish I had known sooner.
👍 266
Reply
2
Bethlyn
Power User
5 hours ago
US stock market intelligence platform offering free tutorials, live market updates, and curated investment opportunities for portfolio optimization. We invest in educating our community because informed investors make better decisions and achieve superior results over time. Our platform provides courses, webinars, and one-on-one coaching to develop your investment skills. Learn from experts and develop winning strategies with our comprehensive educational resources and market insights designed for all levels.
👍 264
Reply
3
Kaiya
Engaged Reader
1 day ago
Gives a clear understanding of current trends and their implications.
👍 208
Reply
4
Houstin
Active Contributor
1 day ago
Expert US stock management team analysis and board composition review for governance quality assessment. We analyze leadership track record and board effectiveness to understand the quality of decision-makers at your portfolio companies.
👍 299
Reply
5
Gloria
Active Reader
2 days ago
The market is showing mixed signals today, with investors keeping a close eye on both domestic and global news.
👍 76
Reply
© 2026 Market Analysis. All data is for informational purposes only.